REVIEWS  AN UPDATE ON MOLECULAR IMAGING OF PROSTATE CANCER (Part I) 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2012 August;56(4):367-74

Copyright © 2012 EDIZIONI MINERVA MEDICA

lingua: Inglese

PET/CT in prostate cancer: non-choline radiopharmaceuticals

Castellucci P. ¹, Jadvar H. ² ✉

¹ Nuclear Medicine Unit, Policlinico S. Orsola-Malpighi, Bologna, Italy; ² Department of Radiology, University of Southern California, Los Angeles, CA, USA

In this brief review, the major potential clinical applications of 18F-FDG, 11C-acetate, 18F-FDHT, 18F-FLT, 18F-FMAU, and anti-18F-FACBC in the imaging evaluation of men with prostate cancer are discussed. 18F-FDG has a limited role in primary diagnosis and staging but it may be able to reflect tumour aggressiveness, detect sites of recurrence in some men with high serum PSA after biochemical failure and assess response to chemo- and hormonal treatment in metastatic disease. 11C-acetate has been investigated for intra-prostatic primary tumour detection and staging as well as for re-staging in case of biochemical relapse with results that are overall similar to those with 18F- and 11C-labeled choline. 18F-FDHT targets the androgen receptor and may be particularly useful in the assessment of the pharmacodynamics of the androgen signalling pathway. PET in conjunction with 18F-FLT or 18F-FMAU that track the thymidine salvage pathway of DNA synthesis has also been investigated for imaging cellular proliferation in prostate cancer. Initial exprience with the radiolabeled synthetic amino acid, anti-18F-FACBC, which displays slow urinary excretion has been encouraging but further studies will be needed to decipher its exact role in the imaging management of men with prostate cancer.